Leandro Jonata Carvalho Oliveira, Medical Oncologist at Oncoclínicas Group, shared a post on LinkedIn:
“Medicare just issued coverage for the Next Personal assay — an ultrasensitive, tumor-informed MRD test — for recurrence monitoring in early breast cancer across all subtypes.
This is now the second MRD assay reimbursed by Medicare for breast cancer, joining Signatera.
We have to remember that we still lack solid clinical-utility data, which will be essential to define how these tools should guide breast cancer care in early stage.
I had the chance to present on this exact topic during the Brazilian Society of Medical Oncology annual meeting last weekend. The session made clear that the field is full of promise, but also full of unanswered questions that will require carefully designed and ongoing clinical trials.”
More posts featuring Leandro Jonata Carvalho Oliveira.